Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance

Abstract

QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA.

The association between medication non‐adherence and adverse health outcomes in ageing populations: A systematic review and meta‐analysis

“…The included studies focussed on a wide range of disease areas including pulmonary diseases, osteoporosis, depression, cardiovascular diseases, Parkinson's disease, epilepsy, chronic kidney disease, cancer and diabetes mellitus . Two studies did not measure disease‐specific medication (non‐)adherence .…”

“…Two studies did not measure disease‐specific medication (non‐)adherence . Thirty‐six studies were specific to, or provided age stratified analysis for people aged ≥64 years, while the other 30 studies also included middle aged adults (≥50 years) . Thirteen authors of the included texts were contacted via e‐mail for further information, and 8 replied.…”

“…Thirteen authors of the included texts were contacted via e‐mail for further information, and 8 replied. In terms of adherence measurement, 54 studies measured medication (non‐)adherence using pharmacy claims data while 11 studies used self‐report methods, consisting of the 4‐item or 8‐item Morisky Medication Adherence Scale, or self‐reported PDC and MEMs was used in 4 studies …”

“…Overall, 48 studies were determined to be high quality, 17 were determined to be medium quality and 1 study was deemed to be low quality (Table S8). There was considerable variability with regards to external validity (generalisability), with 15 studies deemed medium quality and 11 studies achieving low quality . This was due to lack of detail on sampling or recruitment procedures or inclusion of specific populations only.…”

“…Medication adherence was not significantly associated with respiratory specific HRQoL in a study of chronic obstructive pulmonary disease (COPD) patients, but this may have been due to the small sample size ( n = 62) . Two studies compared the average HRQoL score across adherent and non‐adherent patient groups . In the first study, atrial fibrillation patients adherent to rivaroxaban reporting significantly higher QoL scores overall and across all individual domains than non‐adherent patients, while, in the second study, good adherence to antihypertensive treatment was associated with higher HRQoL scores across all domains using the WHOQOL‐BREF, but not with the death and intimacy sections of the WHOQOL‐OLD…”